Mirapexin (Pramipexole Dihydrochloride Monohydrate)

Pramipexole Dihydrochloride Monohydrate, the active ingredient in Mirapexin, is a dopamine agonist presented as an oral tablet for oral use. It stimulates dopaminergic activity in the brain, helping to improve motor control in Parkinson's disease and to reduce uncomfortable sensations in restless legs syndrome for adult patients.

GNH USA supplies Mirapexin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pramipexole acts on the dopaminergic pathway and is indicated for the following conditions:

- Parkinson's disease: improves motor symptoms such as tremor, rigidity and bradykinesia. - Restless legs syndrome: reduces the urge to move the legs and associated discomfort. - Early Parkinsonian syndrome: helps delay the need for levodopa therapy by enhancing dopamine signaling.

Pramipexole may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: sensation of light‑headedness, especially on standing. - Somnolence: increased sleepiness or fatigue. - Headache: mild to moderate tension‑type headaches. - Constipation: reduced bowel movements. - Insomnia: difficulty initiating or maintaining sleep.

Serious or Rare Side Effects: - Hallucinations: visual or auditory disturbances, particularly in older patients. - Impulse control disorders: compulsive gambling, shopping, or eating. - Severe hypotension: marked drop in blood pressure causing faintness. - Sudden onset of sleep: unexpected sleep episodes during daily activities. - Allergic reactions: rash, swelling, or anaphylaxis in rare cases.

When prescribing pramipexole, clinicians should consider the following precautions: - Assess renal function: dose may need adjustment in patients with impaired clearance. - Monitor for impulse control disorders: watch for compulsive behaviors such as gambling or excessive shopping. - Evaluate cardiovascular status: orthostatic hypotension can occur, especially at treatment initiation. - Avoid abrupt discontinuation: tapering is recommended to prevent withdrawal symptoms. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Pramipexole can interact with other medicines; notable interactions include:

Major Interactions (Avoid): - MAO‑B inhibitors: risk of hypertensive crisis when combined. - Antipsychotics (dopamine antagonists): may diminish pramipexole efficacy. - Strong CYP2D6 inhibitors: can increase plasma concentrations of pramipexole.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood‑pressure‑lowering effect. - Alcohol: may enhance central nervous system depression. - Other dopaminergic agents: increased risk of side‑effects such as nausea or hallucinations.